GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Future 3-5Y EPS without NRI Growth Rate

ARDS (Aridis Pharmaceuticals) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Oct. 31, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate is N/A.


Competitive Comparison of Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate falls into.



Aridis Pharmaceuticals  (OTCPK:ARDS) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Aridis Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Aridis Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
N/A
Address
983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Executives
Vu Truong director, 10 percent owner, officer: CEO, CSO, Director 5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer director, 10 percent owner 5941 OPTICAL CT., SAN JOSE CA 95138
Fibrosis Foundation Cystic 10 percent owner 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri officer: Chief Medical Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
John F Hamilton director 1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak officer: Chief Financial Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland officer: Chief Financial Officer C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer officer: Chief Medical Officer 5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo director
Shawn Lu director C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin director 5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025